Thursday, November 17, 2011

Hall of Fame or Shame - We'll know soon

Read,understand and consent to the blog's disclaimer before proceeding

List of analysts that have been bullish recently on $AMRN. Of course lot of these are probably sell side research analysts and likely have some IB business with Amarin.

Jon LeCroy @ Hapoalim Securities
Thomas Wei @ Jeffries
Joseph Schwartz @ Leerink
Ritu Baral @ Canaccord Genuity
David Kestenbaum @ Morgan Joseph TriArtisan

David Kestenbaum @ Morgan Joseph TriArtisan  08/22/2011
he called a "blockbuster opportunity" and said will benefit from demand for triglyceride-lowering drugs. "We wouldn't be surprised if this company gets taken out by one of the larger pharma companies, and it's been proven to be pretty safe so far," Kestenbaum said.

Thomas Wei @ Jeffries 11/16/2011
 The release of additional study results "contained no significant surprises," Jefferies analyst Thomas Wei said in a research note. He added that he remains bullish on the drug's changes for regulatory approval, and a decision is expected by next year's third quarter.

Ritu Baral @ Canaccord Genuity 11/16/2011
"Reiterate rating and price target on commercial, partnership potential of AMR101. AMR101 is Amarin’s 96% EPA omega-3 drug for very high triglycerides (TG). AMRN submitted AMR101’s NDA for high TG in Q3/11. We think AMR101 will be approved mid-2012. We expect significant progress in IP and business development in H2/12." "Unclear how higher bioavailability will translate into TG/non--HDL--C reduction. While Epanova bioavailability data is compelling, experts noted they are still uncertain if it translates to greater triglyceride/non-HDL-C reduction.",+but+Benefit+to+Lipids+Still+Unclear/6950157.html

Joseph Schwartz @ Leerink, 04/18/2011, 11/14/2011
Leerink Swann, which places its peak sales estimates for the drug at $3.2 billion by 2021, believes that the efforts of a pharma partner could drive sales even higher than that estimate.
”Amarin represents an attractive takeover target for multiple large pharmaceutical companies facing a patent cliff,” Schwartz says. Amarin’s drug “has unique qualities that may result in a better product profile than other blockbuster drugs used to lower triglycerides,” Schwartz says in a recent note.

Amarin weakness today a buying opportunity, says LeerinkLeerink believes the non-final patent rejection posted on the USPTO website is part of the normal patent process and recommends using today's pullback in Amarin shares as a buying opportunity. Leerink thinks the website post could even be viewed positively since the communication came quickly, possibly suggesting the remaining issues are minor. The firm reiterates an Outperform rating on the stock. :theflyonthewall.
Amarin reiterated Outperform after call with patent specialists at Leerink
 Morgan Joseph TriArtisan 09/07/2011,11/08/2011
09:27 EDT Amarin AMR101 data positive, says Morgan Joseph
After data was presented for Amarin's treatment for very high triglycerides, Morgan Joseph believes the results added to confidence that the treatment can positively impact cardiac outcomes. The firm thinks competitive concerns surrounding the drug are overblown and it reiterates a Buy rating on Amarin. (AMRN)
Morgan Joseph believes that concerns about Amarin's patent for AMR101 have been "unwarranted and overblown." The firm continues to expect the NDA filing for AMR101 in the hypertriglyceridemia indication to be accepted in coming weeks and it maintains a Buy rating. :

Jon LeCroy @ Hapoalim Securities , 01/18/2011
LeCroy thinks AMR101, Amarin’s lead product, could have peak annual sales of $1 billion and values a potential acquisition of them at around $4 billion. By the way, they have Amarin rated as a ‘Buy’ with a $12 price target. 
(This is before Anchor results)


  1. This blog is great source of information which is very useful for me. Thank you very much.

    elevated triglycerides

  2. Two years later, what do you think? Would you go in now, or do you think that ratings were inflated? I am aware of the clinical benefit of their main product.